AusperBio
Foster City
About AusperBio
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $237.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2025)
- Website: ausperbio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ausperbio-46026 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.